A prospective study on behavioral symptoms’ impact to the quality of life in patients with early-stage cancer receiving radiotherapy.

2013 ◽  
Vol 31 (26_suppl) ◽  
pp. 46-46
Author(s):  
Canhua Xiao ◽  
Jennifer Felger ◽  
Donna Mister ◽  
Tian Liu ◽  
Andrew H. Miller ◽  
...  

46 Background: Fatigue, sleep problems, and depression are the most common behavioral symptoms experienced by breast cancer patients. The purpose of this study was to examine these behavioral symptoms’ impact on quality of life (QOL) for early stage breast cancer patients receiving radiotherapy (RT). Methods: This was a prospective study of 46 patients receiving whole breast RT (50 Gy plus a 10 Gy boost) following lumpectomy. Data were collected at pre-RT, week 6 of RT, and 6-weeks post-RT. QOL was measured by Short Form-36, fatigue by Multidimensional Fatigue Inventory, sleep by Pittsburgh Sleep Quality Index, depression by Inventory for Depressive Symptomatology-Self-Rated, and stress by Perceived Stress Scale. No patients were treated with chemotherapy. Demographic/clinical variables, including age, race, marriage, smoking history, hormone treatment, and cancer stage, were collected at the time of enrollment. Mixed effect modeling was utilized to observe behavioral symptoms’ impact on QOL over time. Results: Fatigue and depression, along with stress, had significant impact on QOL after controlling for body mass index (BMI; the only one significant demographic/clinical variable; see Table). Patients with more fatigue, depression, or stress were more likely to have worse QOL during and post-RT. Patients having a higher BMI at baseline also reported worse QOL over time. Sleep was significantly correlated with QOL in univariate analyses, while this effect disappeared in multivariate models. Conclusions: Behavioral symptoms, in particular fatigue and depression, along with stress, have significant impact on the QOL of early breast cancer patients’ receiving RT. Future research on the underlying biological mechanisms will improve our understanding of these symptoms and their relationships, which will help to find potential targets for multiple related symptoms and, ultimately, improve patients’ QOL. [Table: see text]

The Breast ◽  
2005 ◽  
Vol 14 (3) ◽  
pp. 201-208 ◽  
Author(s):  
Elisabeth Edström Elder ◽  
Yvonne Brandberg ◽  
Tina Björklund ◽  
Richard Rylander ◽  
Jakob Lagergren ◽  
...  

2016 ◽  
Vol 294 (3) ◽  
pp. 639-645 ◽  
Author(s):  
Panayiotis Eskitzis ◽  
Menelaos Zafrakas ◽  
Alexios Papanicolaou ◽  
Efcharis Panagopoulou ◽  
Michael Gkoutzioulis ◽  
...  

2016 ◽  
Vol 1 (1) ◽  
pp. 10-16 ◽  
Author(s):  
Canhua Xiao ◽  
Andrew H. Miller ◽  
Jennifer Felger ◽  
Donna Mister ◽  
Tian Liu ◽  
...  

1998 ◽  
Vol 16 (4) ◽  
pp. 1380-1387 ◽  
Author(s):  
C Lindley ◽  
S Vasa ◽  
W T Sawyer ◽  
E P Winer

PURPOSE To evaluate the quality of life (QOL) of breast cancer patients who survived 2 to 5 years following initiation of adjuvant cytotoxic and/or hormonal therapy and to characterize relationships between QOL and patient physical symptoms, sexual function, and preferences regarding adjuvant treatment. PATIENTS AND METHODS Eighty-six patients who had completed systemic adjuvant therapy for early-stage breast cancer between 1988 and 1991 were surveyed by written questionnaire and telephone interview. Sociodemographic information was obtained for each patient, and patients were asked to complete the Functional Living Index-Cancer (FLIC), the Symptom Distress Scale (SDS), the Medical Outcomes Study (MOS) Short Form 36 (SF-36), a series of questions regarding sexual function, and a survey about preferences for adjuvant therapy in relation to possible benefit. RESULTS The mean FLIC score among all patients was 138.3 (+/- 12.2), which suggests a high level of QOL. The reported frequency of moderate to severe symptoms was generally low (ie, < 15%), with fatigue (31.4%), insomnia (23.3%), and local numbness at the site of surgery (22.1%) occurring with greatest frequency. Patients reported a wide range of sexual difficulties. Preference assessment showed that more than 65% of patients were willing to undergo 6 months of chemotherapy for a 5% increase in likelihood of cancer cure. CONCLUSION Self-rated QOL in breast cancer patients 2 to 5 years following adjuvant therapy was generally favorable. Less than one third of patients reported moderate to severe symptoms. Selected aspects of sexual function appeared to be compromised. The majority of patients indicated a willingness to accept 6 months of chemotherapy for small to modest potential benefit.


Sign in / Sign up

Export Citation Format

Share Document